This episode examines the persistent barriers that contribute to the delayed diagnosis of hidradenitis suppurativa, highlighting the need for greater disease awareness, proactive screening by frontline providers, and the growing role of patient self-advocacy in improving earlier detection.
This episode explores the multidimensional burden of hidradenitis suppurativa, highlighting its physical, emotional, and economic impacts on patients while emphasizing the importance of compassionate care and improved disease recognition.
In this episode, our experts delve into the primary efficacy results of the STOP HS trials, focusing on HiSCR50 at weeks 12 and 24 and how to interpret those numbers.
In this episode, the panelists explore the baseline characteristics of the STOP HS trials and why they matter for interpreting the results and applying them to practice. They first emphasize the achievement of running a >1,200‑patient, global phase 3 HS program, urging clinicians everywhere to refer patients to clinical trials to keep building robust data.
Mark Lebwohl, MD, discusses how the 487-GEP test may help clinicians identify the most appropriate systemic therapy for patients with AD earlier in the treatment journey.
Red light–activated photodynamic therapy offers an effective field-based option for treating both visible and subclinical actinic keratoses.
Dylan Timmermann, PA-C, reflects on the experiences that shaped his career trajectory in dermatology and offers insights relevant to physician assistants and nurse practitioners entering the specialty.
Rethink seborrheic dermatitis care: limit facial steroids, use antifungals wisely, and watch emerging barrier-safe targeted therapies.
Early seborrheic dermatitis treatment reduces inflammation, prevents worsening, and boosts quality of life; experts explain pediatric vs adult goals and mask-triggered flares.
Experts discuss strategies for managing patient remission in psoriatic arthritis, emphasizing personalized treatment plans and ongoing patient engagement.
Explore the impact of patient-centered approaches in dermatology, emphasizing long-term success and quality of life in psoriasis treatment.
Dr. Madigan explains that for a patient with newly diagnosed indolent systemic mastocytosis (ISM), initial management focuses on best supportive therapies like cetirizine and cromolyn sodium while emphasizing that an epinephrine auto-injector is a mandatory component of care due to high anaphylaxis risks.
Ruiz Dasilva emphasized case-based strategies for managing complex inflammatory dermatoses, highlighted chronic pruritus as an urgent unmet need, and called for more standardized designs for atopic dermatitis trials.
James Del Rosso, DO, shares rapid-fire insights on mentorship, HS advances, contact dermatitis triggers, and teen skin care marketing concerns.
This episode, titled Seborrheic Dermatitis Across Skin Tones and Long-Term Disease Burden, features dermatology experts discussing the following critical questions: How might presentation of SD differ in various skin tones? What challenges do you encounter when diagnosing SD in patients with skin color? In your experience, what long-term complications arise when SD is inadequately treated or remains uncontrolled over time?
Seborrheic dermatitis varies by age, affects scalp and face, drives itching and stigma, and lowers quality of life—highlighting newer targeted treatments.
Recent data reveals insights on psoriasis treatment, highlighting the importance of achieving full clearance for long-term control and patient outcomes.
Healthcare professionals discuss evaluating disease control and treatment response using objective findings and patient assessments in dermatology.
At Winter Clinical Miami, Lisa Swanson, MD, FAAD, shared practical, prior authorization–free treatment strategies while calling for expanded therapeutic options and earlier research inclusion for children under 12.
Nicholas Brownstone, MD, showcased multidisciplinary collaboration and educational podcast initiatives aimed at supporting both dermatology trainees and patients.
Harrison Nguyen, MD, MBA, MPH, FAAD, shares early career billing, coding, and mentorship tips for dermatologists at Winter Clinical Miami 2026.
At Winter Clinical Miami 2026, Linda Stein Gold, MD, FAAD, shared acne and rosacea tips and previewed psoriasis oral advances like icotrokinra.
Mark Lebwohl, MD, shares his Winter Clinical Miami 2026 highlights, including oral psoriasis peptides, atopic dermatitis advances, GLP-1 combos, and more.
Systemic mastocytosis often hides behind common symptoms; learn why early, team-based diagnosis and tailored staging prevent delays and risks.
In a Derm Dispatch discussion, Renata Block, DMSc, MMS, PA-C, and Lauren Madigan, MD, review practical strategies for diagnosing and managing cutaneous mastocytosis across age groups.
Patricia M. Delgado, DNP, AGPCNP, DCNP, PMHNP, and Shanna Miranti, MPAS, PA-C, discuss how “taking off the clinician mask” can strengthen trust and improve shared decision-making in the exam room.
In this first episode, Dr. Hadar Lev-Tov and Dr. Martina Porter convene for a clinical journal club to discuss the emerging landscape of Hidradenitis Suppurativa (HS) treatment.
Joni Jefferson, DO, spotlights skin of color dermatology, safer lasers, mentorship, and the future of aesthetic medicine during Black History Month.
In an interview with Dermatology Times, Michael O’Donoghue, MD, describes how a standardized protocol supports efficient and consistent delivery of photodynamic therapy.
BE HEARD long-term data show bimekizumab (Bimzelx) IL‑17A/F reduces hidradenitis suppurativa draining tunnels while boosting IHS4 and quality of life.
